We take risks and challenge the status quo because disease must be fought with unexpected practice.
Unlike traditional therapeutic approaches that target growth factors in their active states, Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors with the aim of avoiding toxicity and improving efficacy.Learn About Our Science
Scholar Rock works across therapeutic areas and shines new light on the overlooked to better target disease.
Our growing team is replete with good people who eat, sleep, and breathe good science. We promote a spirit of inquiry outside one’s traditional expertise to uncover enlightened solutions for patients.
Spinal Muscular Atrophy
In partnership with Gilead Sciences
November 12, 2020
Scholar Rock to Present at Upcoming Healthcare Conferences
November 9, 2020
Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress
November 2, 2020
Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
EventsView More Events
December 1, 2020
Piper Sandler 32nd Annual Virtual Healthcare Conference
November 19, 2020
Jefferies Virtual London Healthcare Conference
October 27, 2020
TOPAZ Interim Analysis: SRK 015 Demonstrates Clinical Proof of Concept in Spinal Muscular Atrophy